Rediscovering How We Treat Kidney Cancer
and Modify Risky Behavior
New data that emerges from ongoing clinical trials of targeted therapies hold our attention throughout the year, and in recent years these new agents have vastly expanded the treatment spectrum. Although such news tends to overshadow other studies—such as those presenting epidemiologic data—it is worthwhile to turn our attention from time to time to basic research that gives us insights and benchmarks
for evaluating our treatment paradigms and strategies to modify risk.
”To continue reading the Editor's Memo, click here.
To read features and articles in the journal, click on the titles below.
Abstracts from the European Society of Medical
Oncology and the European Multidisciplinary Cancer Congress, Stockholm , September 23-27, 2011
The European Multidisciplinary Cancer Congress reported an attendance of almost 16,000 from 116 countries, according to the European Society of Medical Oncology (ESMO).
GUEST EDITOR'S MEMO
